Your Feed

Filter by
See content from
Back to the latest
Thumbnail for Phase 1 Therapy PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023
Playlist: ASCO 2023

Phase 1 Therapy PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023

Video details & playlist
Thumbnail for DREAMM-3 - Blenrep (Belmaf) vs. PomDex for Relapsed/Refratory Myeloma | Katja Weisel, MD | ASCO 2023
Playlist: ASCO 2023

DREAMM-3 - Blenrep (Belmaf) vs. PomDex for Relapsed/Refratory Myeloma | Katja Weisel, MD | ASCO 2023

Video details & playlist
Thumbnail for Barriers in Accessing Myeloma Care in Special Populations | Shakira Grant, MBBS | ASCO 2023
Playlist: ASCO 2023

Barriers in Accessing Myeloma Care in Special Populations | Shakira Grant, MBBS | ASCO 2023

Video details & playlist
Thumbnail for Results of Bispecific Antibody Combination in Advanced Myeloma | Yael Cohen, MD | ASCO 2023
Playlist: ASCO 2023

Results of Bispecific Antibody Combination in Advanced Myeloma | Yael Cohen, MD | ASCO 2023

Video details & playlist
Thumbnail for Bispecific Antibody Therapy in Relapsed/Refractory Myeloma | Meera Mohan, MD, MS, FACP | ASCO 2023
Playlist: ASCO 2023

Bispecific Antibody Therapy in Relapsed/Refractory Myeloma | Meera Mohan, MD, MS, FACP | ASCO 2023

Video details & playlist
Thumbnail for Advancements in AML & MDS: Genetic Sequencing & Immune Therapies | David Swoboda, MD | ASCO 2023
Playlist: ASCO 2023

Advancements in AML & MDS: Genetic Sequencing & Immune Therapies | David Swoboda, MD | ASCO 2023

Video details & playlist
Thumbnail for Advancements in AML & MDS: Genetic Sequencing & Immune Therapies | David Swoboda, MD | ASCO 2023
Playlist: ASCO 2023

Advancements in AML & MDS: Genetic Sequencing & Immune Therapies | David Swoboda, MD | ASCO 2023

Video details & playlist
Thumbnail for LINKER-MM1 Study: Linvoseltamab (REGN5458) in Relapsed/Refractory Myeloma | Hans Lee, MD | ASCO 2023
Playlist: ASCO 2023

LINKER-MM1 Study: Linvoseltamab (REGN5458) in Relapsed/Refractory Myeloma | Hans Lee, MD | ASCO 2023

Video details & playlist
Avatar
Qunbin
Multiple Myeloma Discussion • June 3, 2023
Understanding Treatment Outcomes: Helpful Resource
AI-generated title
Measuring Treatment Response for Myeloma: https://www.lls.org/myeloma/treatment/treatment-outcomes With the current advances in treatment and supportive care, survival rates for myeloma patients have improved significantly in the last decades. It is not unusual for myeloma patients to live for 10 years or longer after diagnosis. Outcomes are influenced by a series of patient-specific factors, including disease stage, chromosome abnormalities, age, and the presence of other medical problems. Patients should discuss their own potential outcomes with their doctors.
Multiple Myeloma | Treatment Outcomes for Multiple Myeloma | LLS

Multiple Myeloma | Treatment Outcomes for Multiple Myeloma | LLS

Your doctor must monitor your response to treatment for myeloma. By measuring your progress, your doctor can see whether changes to your treatment are needed.

https://www.lls.org/myeloma/treatment/treatment-outcomes